Strong clinical performance remains essential—but sustained commercial success increasingly depends on how effectively companies align pricing, access, targeting, and competitive positioning

We're keeping Eyes On Diabesity. With new approvals, data on the horizon, and M&A to bolster pipelines, it seems like there's something new everyday. Here we cover new MACE indications and the Metsera bidding war. What were you watching?

We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...